Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.

In this article, the authors reported that calcipotriol/betamethasone dipropionate aerosol foam significantly improved scalp psoriasis symptoms in three patients by reducing itching and improving flaky patches within a four-week treatment period, confirming its efficacy and enhanced skin penetration compared to older formulations.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

This review reports no new results and discusses various topical treatments, noting that fluocortin butyl ester offers anti-inflammatory effects without systemic side effects, while combinations outperform single-agent therapies in managing hyperpigmentation.

This study found that while flutamide was very effective in improving hirsutism in women over long-term treatment, a high incidence of adverse effects led to a majority discontinuing the therapy.

This study found that bulge keratinocytes in mice develop resistance to glucocorticoid treatment more slowly than interfollicular keratinocytes and do not significantly aid in repairing glucocorticoid-induced skin atrophy within five days.

This study found that betamethasone valerate in a foam vehicle has comparable total coverage to traditional topical corticosteroid vehicles, despite less coverage per unit of foam.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

In this study, the researchers found no superiority of combining 308-nm excimer laser with intralesional corticosteroid over corticosteroid alone for treating frontal fibrosing alopecia, and reported side effects such as erythema and postinflammatory hyperpigmentation in both treatment groups.

This review explores current therapeutic options for frontal fibrosing alopecia, noting the use of finasteride, topical tacrolimus, hydroxychloroquine, and excimer laser in managing the condition, but reports no new clinical results.

In this clinical experience, treating frontal fibrosing alopecia with oral finasteride, hydroxychloroquine, tacrolimus, and excimer laser was associated with optimal results in patients with active inflammation.

In this case report, topical application of fluocinolone acetonide acetate ointment increased hair length and thickness in three family members with congenital hypotrichosis.

This study found that combining oral isotretinoin with topical treatments was more effective than topical treatments alone for improving frontal fibrosing alopecia symptoms, despite some side effects.

In this study, low doses of cyproterone acetate with ethinylestradiol were as effective as low-dose flutamide in reducing acne severity in hyperandrogenic women, while finasteride was less effective.

This study found that in patients with frontal fibrosing alopecia, combining topical tacrolimus with isotretinoin is more effective after four weeks of treatment compared to tacrolimus with finasteride, though both regimens offered some benefit.

This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.

This case report found that a woman's hair loss, which progressed while using spironolactone and topical minoxidil, reversed after switching to flutamide therapy.

In this study, both finasteride and hydroxychloroquine were found to be equally effective, safe, and well-tolerated first-line treatments for frontal fibrosing alopecia in female patients, with no significant differences in efficacy between the two therapies over six months.

This study found that flutamide-induced liver toxicity in prostate cancer patients was very rare, occurring in only 0.18% of cases with clinical manifestations, and symptoms resolved after discontinuing the drug.

In this report, researchers described a 36-year-old woman with frontal fibrosing alopecia resistant to standard treatments, who showed significant improvement after six months on a combination of intralesional betamethasone and oral hydroxychloroquine, suggesting potential benefits of this therapy approach in managing the condition.

This study found that spironolactone, flutamide, and finasteride are similarly effective in reducing hair diameter and Ferriman-Gallwey scores in women with hirsutism over a 6-month treatment period.

This study found that a topical lotion containing minoxidil, hydrocortisone butyrate, and 17α-estradiol improved or stabilized frontal fibrosing alopecia in 35 out of 40 women over 36 months.

This study observed that topical flutamide may be as effective as hydroquinone for treating melasma, with a trend towards greater improvement and patient satisfaction, but recommends further research before clinical use.

This report describes a case where a woman with frontal fibrosing alopecia initially presented with symptoms resembling rosacea, but further investigation led to a diagnosis of FFA, resulting in a treatment change to oral finasteride and hydroxychloroquine.

This study observed that hepatotoxicity is a rare but possible event in hyperandrogenic young females treated with low- and ultralow-dose flutamide, regardless of dose or oral contraceptive use.

This clinical trial found that transdermal delivery of 5-Fluorouracil using fractional CO2 laser resulted in a significantly better treatment response in alopecia areata patients compared to intralesional injections of the same drug, with a greater reduction in the Severity of Alopecia Tool Score.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

This study found that combining Flutamide and an LHRH agonist in adult male rats effectively inhibited prostatic growth and reduced androgen-sensitive prostatic activity markers to levels similar to castrated rats.

This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.